tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ascendis Pharma price target raised to $230 from $210 at RBC Capital
PremiumThe FlyAscendis Pharma price target raised to $230 from $210 at RBC Capital
21d ago
Ascendis Pharma price target raised to $307 from $306 at UBS
Premium
The Fly
Ascendis Pharma price target raised to $307 from $306 at UBS
21d ago
Ascendis Pharma price target raised to $290 from $243 at Citi
Premium
The Fly
Ascendis Pharma price target raised to $290 from $243 at Citi
21d ago
Ascendis Pharma Reports Increased Revenue but Sustained Losses in H1 2025
PremiumCompany AnnouncementsAscendis Pharma Reports Increased Revenue but Sustained Losses in H1 2025
22d ago
Ascendis Pharma reports Q2 EPS (EUR 0.82) vs. (EUR 2.21) last year
Premium
The Fly
Ascendis Pharma reports Q2 EPS (EUR 0.82) vs. (EUR 2.21) last year
22d ago
Ascendis Pharma Reports Strong Q2 2025 Results and Advances Key Therapies
Premium
Company Announcements
Ascendis Pharma Reports Strong Q2 2025 Results and Advances Key Therapies
22d ago
Ascendis Pharma announces FDA approved SKYTROFA
PremiumThe FlyAscendis Pharma announces FDA approved SKYTROFA
1M ago
Ascendis Pharma’s Strong Market Performance and Potential Drive Buy Recommendation
Premium
Ratings
Ascendis Pharma’s Strong Market Performance and Potential Drive Buy Recommendation
1M ago
Ascendis Pharma’s Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating
Premium
Ratings
Ascendis Pharma’s Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100